Skip to main content
  • Notice of Privacy Incident
  • Medicaid Provider Termination Alert: Revalidation deadlines are approaching. Failure by providers to revalidate will lead to termination and payment suspension. Check your account now at https://impact.illinois.gov/ to learn if your required revalidation is due this month. More revalidation information here.
Elizabeth M. Whitehorn, Director

Drugs and Therapeutics (D & T) Committee Drugs Under Review for: September 23, 2009

Drug Name Review Type Class Manufacturer
Besivance New Drug Initial Review Ophthalmic Fluoroquinolone Bausch & Lomb
Nascobal New Drug Initial Review Vitamin Par
Santyl Ointment New Drug Initial Review Wound Care Healthpoint
Toviaz New Drug Initial Review Urinary Anti-Incontinence Pfizer
Momexin New Drug Initial Review Topical Corticosteroid JSJ
Nucynta New Drug Initial Review Narcotic Ortho-McNeil-Janssen/J&J
Bromfed DM New Drug Initial Review Non-Narcotic Cough/Cold Morton Grove/Wockhardt
Invega Sustenna New Drug Initial Review Atypical Antipsychotic Ortho-McNeil-Janssen/J&J
Savella New Drug Initial Review SNRI Forest
Multaq New Drug Initial Review Antiarrhythmic Sanofi Aventis
Saphris New Drug Initial Review Atypical Antipsychotic Schering-Plough
Adcirca New Drug Initial Review Pulmonary Arterial Hypertension United Therapeutics
Onglyza New Drug Initial Review DPP4 Inhibitor BMS
Ulesfia New Drug Initial Review Pediculocide Sciele
Moxatag New Drug Appeal Antibiotic MiddleBrook
PegIntron PDL Appeal Hepatitis C Schering-Plough
Advair PDL Appeal Inhaled Steroid GlaxoSmithKline